Gilead Sciences, Inc. (GILD) stock profile

Frequently asked questions

What does Gilead Sciences, Inc. (GILD) do?

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States, Europe, and internationally. The company offers treatments for HIV/AIDS including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla; Veklury for coronavirus disease 2019; and liver disease treatments such as Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Gilead also provides oncology and cell therapy products including Yescarta, Tecartus, Trodelvy, and Zydelig for hematology patients; Letairis for pulmonary arterial hypertension; Ranexa for chronic angina; and AmBisome for serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos NV, Janssen Sciences Ireland, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Dragonfly Therapeutics, and Merck. Incorporated in 1987, Gilead is headquartered in Foster City, California.

Where is GILD stock listed?

Gilead Sciences, Inc. trades under the ticker GILD on NASDAQ.

How can I research GILD's financials and filings?

Vantafin provides Gilead Sciences, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the GILD profile.